WW International Inc Dossier - Source-backed chat

WW International Inc

WWNASDAQ

SectorConsumer Discretionary

IndustrySpecialized Consumer Services

Beta (adjusted)1.57

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $15.46Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $154.6M

Enterprise Value $503.9M

Shares Outstanding 10M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

WW International is undergoing a high-stakes corporate transformation, pivoting from its legacy behavioral weight-loss model to a clinically integrated digital health platform (Med+ and WeightWatchers Clinic). While the clinical segment is showing robust growth (clinical subscribers up 46% YoY in Q1 2026), it is not yet large enough to fully offset the double-digit decline in the legacy behavioral business. Following its mid-2025 Chapter 11 restructuring, which eliminated $1.1 billion in debt, the company's balance sheet is significantly cleaner, but it remains burdened by a high-interest term loan. The investment case is highly binary: if clinical growth can achieve critical mass and stabilize overall revenues before behavioral churn erodes liquidity, the stock offers massive upside. However, near-term execution risks, leadership transitions, and intense competition from telehealth aggregators warrant a cautious Hold stance.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$28.33

High · most bullish analyst$35.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$6.1820%

Behavioral subscriber churn accelerates rapidly due to intense competition from low-cost telehealth aggregators and direct-to-consumer GLP-1 providers. Clinical growth stalls as customer acquisition costs rise due to media inflation. The company fails to generate sufficient free cash flow to comfortably service its expensive term loan, leading to renewed liquidity pressures and equity erosion.

Base CaseCentral scenario

$21.3250%

The company executes its transition in line with guidance. Clinical subscribers grow steadily, reaching approximately 200,000, while behavioral subscriptions continue a moderate decline. Full-year 2026 revenue stabilizes between $620 million and $635 million, with Adjusted EBITDA of $105 million to $115 million. Debt is gradually reduced using cash on hand and annual cash sweeps, keeping liquidity stable but limiting near-term equity expansion.

Bull CaseUpside scenario

$34.5030%

Clinical acceleration drives a complete corporate turnaround. The partnership with Eli Lilly's LillyDirect and the expansion of the Med+ tier (including access to oral semaglutide) accelerate clinical subscriber growth beyond expectations. Behavioral churn stabilizes as the Core+ tier gains traction. High-margin clinical subscriptions expand overall gross margins, driving rapid deleveraging via the mandatory cash sweep and leading to a significant valuation re-rating.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong clinical segment momentum, with clinical subscribers growing 46% YoY to 197,000 in Q1 2026.
High-impact strategic partnerships, such as integration into Eli Lilly's LillyDirect platform, expanding patient access.
Impressive adjusted gross margins remaining near record highs at 73.6% in Q1 2026 due to operational efficiencies.
Successful balance sheet restructuring in 2025 that eliminated over $1.1 billion of debt, buying the company runway to execute its pivot.

Key Investment Risks

Persistent double-digit decline in the legacy behavioral subscriber base, which continues to drag down total revenue.
High cost of remaining debt, with a $465 million term loan priced at high interest rates (~10.5%) straining cash flows.
Intense competition in the clinical weight-loss space from well-capitalized digital health platforms and telehealth aggregators.
Leadership instability, following the departure of CEO Tara Comonte in March 2026 and the operation under an Interim Office of the CEO.

Thesis Invalidation Triggers

Total subscriber count falling below 2.4 million in any fiscal quarter.
Adjusted gross margin compressing below 68% due to rising clinical service delivery costs.
Failure to meet the full-year 2026 revenue guidance floor of $620 million.
Inability to execute the planned $37 million term loan prepayment in Q2 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.